Clinical Trial Update: Early Clinical Study of JY306 Universal NK Cell Injection in the Treatment of Adult Relapsed or Refractory CD70+ Malignant Hematologic Tumors [EARLY_Phase 1]

View source ↗

Summary

An early-phase study evaluating JY306 universal NK cell injections for adults with relapsed or refractory CD70-positive malignant hematologic tumors; the trial …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cd70-positive Malignant Hematologic Tumors
• Hematologic Malignancies

Drugs mentioned

• JY306 Universal NK Cell Injection

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Relapsed or Refractory Hematological Malignancies | EARLY_Phase 1 | Status: NOT_YET_RECRUITING